Introduction: Anti-Tumor Necrosis Factor-alpha (TNF-alpha) therapy, primarily infliximab and adalimumab, are now increasingly used to induce and maintain disease remission in the pediatric perianal Crohn's disease (CD) population, however, their optimal use has not yet been defined in the pediatric setting. Areas covered: In accordance with a published protocol (PROSPERO no. CRD42019118838), we systematically and critically evaluated all published evidence on the efficacy and safety of anti-TNF-alpha in children with perianal CD, in the PubMed, MEDLINE, Embase, Cochrane and clinicalTrials.gov databases until October, 18(th), 2018. We included in our systematic review 29 articles yielding a total of 565 perianal CD patients aged between 9 months to 18 years. Expert opinion: According to low-quality evidence from small, uncontrolled and heterogeneous descriptive studies, and very few randomized controlled trial, nearly three-fifths children with perianal CD achieved remission with anti-TNF-alpha treatment and in approximately 40% remission was maintained after 12 months, with practically low discontinuation rate due to serious adverse events. More than half of the patients achieved complete fistula closure. There is still a need for more robust evidence adequately assessing the efficacy and safety of anti-TNF-alpha therapy in pediatric perianal CD, as well as in comparison with other therapies.

Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn’s disease patients with perianal lesions: a systematic review / C. Carnovale, A. Maffioli, G. Zaffaroni, F. Mazhar, V. Battini, G. Mosini, M. Pozzi, S. Radice, E. Clementi, P. Danelli. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 20:3(2020), pp. 239-251. [10.1080/14712598.2020.1718096]

Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn’s disease patients with perianal lesions: a systematic review

C. Carnovale;A. Maffioli;G. Zaffaroni;F. Mazhar;V. Battini;G. Mosini;E. Clementi;P. Danelli
2020

Abstract

Introduction: Anti-Tumor Necrosis Factor-alpha (TNF-alpha) therapy, primarily infliximab and adalimumab, are now increasingly used to induce and maintain disease remission in the pediatric perianal Crohn's disease (CD) population, however, their optimal use has not yet been defined in the pediatric setting. Areas covered: In accordance with a published protocol (PROSPERO no. CRD42019118838), we systematically and critically evaluated all published evidence on the efficacy and safety of anti-TNF-alpha in children with perianal CD, in the PubMed, MEDLINE, Embase, Cochrane and clinicalTrials.gov databases until October, 18(th), 2018. We included in our systematic review 29 articles yielding a total of 565 perianal CD patients aged between 9 months to 18 years. Expert opinion: According to low-quality evidence from small, uncontrolled and heterogeneous descriptive studies, and very few randomized controlled trial, nearly three-fifths children with perianal CD achieved remission with anti-TNF-alpha treatment and in approximately 40% remission was maintained after 12 months, with practically low discontinuation rate due to serious adverse events. More than half of the patients achieved complete fistula closure. There is still a need for more robust evidence adequately assessing the efficacy and safety of anti-TNF-alpha therapy in pediatric perianal CD, as well as in comparison with other therapies.
Biologic drugs; Crohn's disease; drug safety; pediatrics; Tumor Necrosis Factor
Settore MED/18 - Chirurgia Generale
Article (author)
File in questo prodotto:
File Dimensione Formato  
PDF_Proof.PDF

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 793.69 kB
Formato Adobe PDF
793.69 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/715633
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact